PACS实施中的RFP模板及其应用

通过结合国内医疗体系的现状和借鉴国际上成熟的PACS实施经验,构建了一个RFP模板.该模板从技术、运作和商务三个方面对PACS实施中的需求进行了讨论,从项目概况、系统组成、系统集成等方面对RFP的主要内容进行了分析,并基于QFD技术形成了层次化结构的UR树.该模板经浙江大学医学院附属第一医院在全院PACS系统的实施中应用,表明,是可行的和有效的.     

肉桂中查耳酮的类似胰岛素作用

为了进一步揭示肉桂活性成分的化学物质基础,对肉桂进行综合利用开发.近几年,各国学者对其进行了较为系统的研究,结果发现肉桂中除含有桂皮醛、醋酸树皮酯、桂皮酸、黄酮类等已发现的物质外,还含有另外一种在抑制3T3-L1脂肪类固醇的过程中有类似胰岛素作用的羟基查耳酮类化合物.     

反相高效液相色谱法测定犬血浆中左氧氟沙星浓度及其犬体内药代动力学

目的 :建立测定犬体内左氧氟沙星血药浓度的反相高效液相色谱法 ,并测定其犬体内药代动力学。方法 :以环丙沙星为内标 ,采用 10 %高氯酸为沉淀剂处理犬血浆样品 ,色谱柱为DIKMADiamon silTM C18,5m ,15 0mm× 4 .6mm ,流动相为甲醇 PBS 三乙胺 异丙醇 (33 6 7 0 .14 0 .4 ,用磷酸调pH为 3.0 ) ,流速 1.2ml·min-1,柱温 2 0℃ ,荧光检测(λex=2 95nm ,λem=4 40nm)。结果 :血药浓度线性范围 0 .2 5～ 5 0mg·L-1(r =0 .9998) ,最低检测限浓度为 0 .0 2mg·L-1(S N >3) ,绝对回收率为 83.0 %～85 .6 % (n =5 ) ,方法回收率为 92 .10 %～ 10 6 .77%(n =5 ) ,日内和日间RSD分别为 1.3%～ 4 .0 %和1.8%～ 8.2 % (n =5 )。结论 :本方法简便、灵敏、精密度高 ,重现性好 ,适用于左氧氟沙星犬体内药代动力学研究及生物等效性研究     

高效毛细管电泳法分离测定不同种类甘草药材中甘草酸的含量

目的 应用高效毛细管电泳法(HPCE)测定不同种类甘草药材中甘草酸的含量。方法 缓冲液30mmol·L-1硼酸盐溶液,pH=9.2,未涂层弹性石英毛细管(75 μm×47.5 cm,有效分离长度40 cm)为分离通道,压力进样(250 Kpa·s),20 kV恒压电泳(25 C)分离,254 nm检测。结果 整个分析过程可以在7 min以内完成,甘草酸含量的线性范围为0~500μg·mL-1(r=0.999 7)。甘草酸的保留时间与甘草酸积分峰面积的RSD值分别为0.2％和3.4％。结论 该方法简洁、快速,重现性较好,适用于甘草药材中甘草酸含量的快速测定,也为进一步建立甘草药品的指纹图谱提供了可行性依据,并且,可以同时分析甘草酸的水解产物-甘草次酸,可用于进一步研究甘草类药物的代谢。     

A Case of Secondary Glaucoma due to Bilateral Anterior Chamber Shallowing Caused by Marfan′s Syndrome

Purpose:To report the clinical manifestations and treatment of a case of secondary glaucoma evolving from bilateral anterior chamber flattening caused by Marfan′s syndrome. Methods:The ophthalmic and systemic features,B-scan and UBM characteristics were recorded.Therapy and efficacy were analyzed. Results:Marfans syndrome,in this case,caused bilateral iris-lens diaphragm anterior dislocation,anterior chamber flattening, pupillary block, angle closure,and finally resulted in persistent increased intraocular pressure (IOP). After undergoing pars plana vitrectomy and lensectomy combined with anterior chamber reformation, the visual acuity of the patient’s right eye increased from 6/150 to 6/7.5.(best-corrected) and that of the left eye was improved from 6/100 to 6/10 (best-corrected). The IOP of the right eye fell to 18 mm Hg, and the left eye to 12 mm Hg. Conclusion:Marfan′s syndrome can cause bilateral anterior chambers flattening,and induce secondary angle closure glaucoma.Combined pars plana vitrectomy, lensectomy and anterior chamberplasty can re-form the anterior chamber, control IOP and maintain visual function.     

二氢吡啶类钙拮抗剂结构与药物动力学的定量关系分析

目的：研究二氢吡啶类钙拮抗剂的化学结构与药物动力学的关系，为新药设计中早期筛选提供理论方法。方法：采用Inisht Ⅱ软件的分子力学和分子动力学程序首先将钙拮抗剂的结构式转化为三维结构，并进行能量优化，使得结构趋于合理。HyperChem软件计算优化好的结构的理化性质参数(Log P，Surface Area，Volume，Hydration Energy，Refractivity，Polarizability)。对钙拮抗剂药物的理化参数与其药物动力学参数之间关系进行统计分析研究。结果：钙拮抗剂的疏水性常数(Log P)值与血管外给药后的达峰时间(Tmax)存在二次方程关系，二者的相关性达到0．9以上。结论：二氢吡啶类钙拮抗剂药物的疏水性常数(Log P)值与给药后的达峰时间(Tmax)存在的关系对该类药物的进一步结构改造，设计新药具有重要的指导意义。     

黄芪对感染病毒大鼠心肌细胞L型钙通道的效应

目的:了解黄芪对感染柯萨奇病毒心肌细胞 L 型钙通道的影响,以探讨黄芪用于心肌炎治疗的作用机制。方法:以柯萨奇 B_3病毒感染急性分离的成年大鼠心肌细胞,利用膜片钳技术记录 L 型钙通道电流。结果:黄芪不影响正常心肌细胞 L 型钙通道电流的幅度,但可减缓 L 型钙通道电流的衰减。病毒感染增加心肌细胞 L 型钙通道电流的幅度,并改变其电压依赖性而使电流电压曲线向左下偏移。黄芪可抑制病毒感染细胞 L 型钙通道电流的增加。结论:黄芪通过抑制感染细胞经 L 型钙通道的跨膜钙内流和稳定 L 型钙通道的作用,可防止病毒感染可能导致的细胞内钙超载和异常电活动,从而对感染细胞起到保护作用     

A phase I randomized,double‐blind,single subcutaneous dose escalation study to determine the safety,tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of rezafungin after subcutaneous (s.c.) administration. The study design consisted of six sequential cohorts of eight subjects, except for the first cohort with four subjects. The subjects were randomized in a 3:1 ratio of rezafungin to placebo and were to receive a single dose of 1, 10, 30, 60, 100, or 200 mg. The most common adverse events (AEs) were increased alanine aminotransferase and sinus bradycardia (unsolicited) and erythema at the injection site (solicited). Unsolicited AEs were generally mild to moderate and not rezafungin‐related. Although the study was terminated after the 10 mg dose cohort due to concerns of potential increased severity of injection site reactions, no predetermined dose escalation halting criteria were met. Following the 10 mg single s.c. dose of rezafungin (n = 6), the geometric mean (GM) maximum concentration (C _max) was 105.0 ng/ml and the median time to C _max was 144 h. The GM area under the concentration‐time curve was 32,770 ng*h/ml. The median estimated terminal half‐life was 193 h. The GM apparent oral clearance was 0.255 L/h and the GM apparent volume of distribution was 68.5 L. This study demonstrates that a single s.c. dose of rezafungin in healthy adult subjects: (1) did not result in serious AEs, death, or withdrawal from the study due to an AE; and (2) produced a pharmacokinetic profile with long exposure period postadministration. In an effort to reduce the occurrence of injection site reactions, a re‐evaluation of the rezafungin s.c. formulation could be considered in the future.

Study Highlights

• WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?

Currently marketed antifungal agents of the echinocandin class are dosed by i.v. once daily and are therefore not practical for prolonged or outpatient prophylaxis. Rezafungin is an investigational echinocandin (currently in phase III trials studying once‐weekly i.v. administration) that has excellent activity against clinically relevant Candida and Aspergillus spp. and Pneumocystis jirovecii, a prolonged half‐life allowing for longer dosing intervals, and a stability/solubility profile that allows for the possibility of subcutaneous (s.c.) dosing.

• WHAT QUESTION DID THE STUDY ADDRESS?

The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics (PKs) of rezafungin after s.c. administration.

• WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?

This study provided safety data regarding s.c. administration of rezafungin. Despite common solicited injection site reactions, s.c. administration of 10 mg of rezafungin did not result in serious adverse event (AEs), death, or withdrawals due to an AE in healthy adult subjects. The study also showed that rezafungin had a PK profile with a long exposure period.

• HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?

In an effort to reduce the occurrence of injection site reactions, these findings may lead to a future re‐evaluation of the s.c. formulation of rezafungin.     

人胎盘基因表达谱芯片的初步研究

目的 制备人胎盘基因表达谱芯片,前用于基因差异表达分析。方法用基因芯片点样仪将胎盘基因文库探针打印在氨基包被的玻片上制备表达谱芯片。分别提取对照组三氧化二砷处理的K562细胞总RNA,纯化mRNA后反转录成cDNA。再以限制性显示技术进行荧光标记,将两组荧光标记的样品混合后与芯片进行杂交。杂交后清洗芯片,干燥后对芯片进行扫描,分析杂交结果。结果 建立了较可靠的制备与检测基基表达芯片的方法,并筛选出45个差异表达基因片段。结论 制备的人胎盘基因表达谱芯片可有效地应用于基因的差异表达分析。